Investigating the Effect of Monophosphoryl Lipid A as a Co-adjuvant on Humoral Immune Response against Staphylococcus Aureus Infection in a Mouse Model

Document Type : Original Article(s)

Authors

1 PhD Student, Department of Toxicology and Pharmacology, School of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 Associate Professor, Department of Microbiology, School of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

3 Professor, Department of Toxicology and Pharmacology, School of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

4 Assistant Professor, Department of Toxicology and Pharmacology, School of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

5 Associate Professor, Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Staphylococcus aureus is one of the leading causes of nosocomial infections, therefore, it is necessary to develop a suitable vaccine candidate to prevent infections caused by this bacterium. Autolysin protein as a virulence factor plays an important role in bacterial division. Monophosphoryl lipid A (MPLA) as a Toll-like receptor 4 agonist is currently used as an adjuvant. In this study, autolysin protein along with MPLA was investigated as a vaccine candidate.
Methods: Recombinant autolysin was expressed with IPTG and purified by Ni-NTA affinity chromatography. To increase the immunogenicity of vaccine candidates, Monophosphoryl lipid A (biologic and synthetic) was formulated in combination with Alum in four groups of Balb/c mice. Animals were injected subcutaneously three times at intervals of two weeks. Total IgG and IgG1, IgG2a isotype antibodies were measured in sera by indirect ELISA technique. Then, experimental mice were challenged with a sub-lethal dose of Staphylococcus Strain (5×108 CFU) and following that, the number of bacteria from internal organs was assessed. Also, the survival rate was monitored daily for 30 days.
Findings: Total IgG, IgG1, and IgG2a isotype antibody levels were significantly improved in vaccinated groups in comparison to the control group. Bacterial burden in the internal organ (Liver, spleen, and kidney), and animal mortality of the vaccinated group especially r-Autolysin+Alum+MPLA Synthetic and r-Autolysin+Alum+MPLA biologic were decreased in comparison to the control group.
Conclusion: We concluded that synthetic MPLA is a reliable candidate for immune response improvement against Staphylococcal infection.

Keywords

Main Subjects

Full Text

مهدی میرشکار: Google Scholar

ستاره حقیقت: Google Scholar

سیده زهرا موسوی: Google Scholar

امیر حسین عبد الغفاری: Google Scholar

محمد حسین یزدی: Google Scholar

References

  1. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed 2015; 5(7): 509-14.
  2. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 2013; 26(2): 185-230.
  3. Ranjbariyan A, Haghighat S, Yazdi MH, Arbabi Bidgoli S. Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus. World J Microbiol Biotechnol 2023; 39(1): 16.
  4. Tiwari KB, Gatto C, Walker S, Wilkinson BJ. Exposure of Staphylococcus aureus to targocil blocks translocation of the major autolysin Atl across the membrane, resulting in a significant decrease in autolysis. Antimicrob Agents Chemother 2018; 62(7): e00323-18.
  5. Houston P, Rowe SE, Pozzi C, Waters EM, O'Gara JP. Essential role for the major autolysin in the fibronectin-binding protein-mediated Staphylococcus aureus biofilm phenotype. Infect Immun 2011; 79(3): 1153-65.
  6. Mortazavi SS, Haghighat S, Mahdavi M. Recombinant PBP2a of methicillin-resistant S. aureus formulation in Alum and Montanide ISA266 adjuvants induced cellular and humoral immune responses with protection in Balb/C mice. Microb Pathog 2020; 140: 103945.
  7. Pasztor L, Ziebandt A-K, Nega M, Schlag M, Haase S, Franz-Wachtel M, et al. Staphylococcal major autolysin (Atl) is involved in excretion of cytoplasmic proteins. J Biol Chem 2010; 285(47): 36794-803.
  8. Haghighat S, Siadat SD, Sorkhabadi SMR, Sepahi AA, Mahdavi M. A novel recombinant vaccine candidate comprising PBP2a and autolysin against Methicillin Resistant Staphylococcus aureus confers protection in the experimental mice. Mol Immunol 2017; 91: 1-7.
  9. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65(20): 3231-40.
  10. Alemalhoda D, Ajamian F, Khorasani A, Haghighat S, Amreie MM, Moghadas FSS, et al. Formulation of FMD vaccine in Naloxone/Alum mixture: A potency study. bioRxiv 2022.
  11. Haghighat S, Siadat SD, Sepahi AA, Mahdavi M. Recombinant PBP2a/autolysin conjugate as PLGA-based nanovaccine induced humoral responses with opsonophagocytosis activity, and protection versus methicillin-resistant Staphylococcus aureus infection. Iran J Basic Med Sci 2022; 25(4): 442-50.
  12. Pérez O, Romeu B, Cabrera O, González E, Batista-Duharte A, Labrada A, et al. Adjuvants are key factors for the development of future vaccines: lessons from the finlay adjuvant platform. Front Immunol 2013; 4: 407.
  13. Schijns VEJC, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10(4): 539-50.
  14. Chen C, Zhang C, Li R, Wang Z, Yuan Y, Li H, et al. Monophosphoryl-lipid A (MPLA) is an efficacious adjuvant for inactivated rabies vaccines. Viruses 2019; 11(12): 1118.
  15. Di Lorenzo F, Kubik Ł, Oblak A, Lore NI, Cigana C, Lanzetta R, et al. Activation of Human Toll-like receptor 4 (TLR4)· myeloid differentiation factor 2 (MD-2) by hypoacylated lipopolysaccharide from a clinical isolate of Burkholderia cenocepacia. J Biol Chem 2015; 290(35): 21305-19.
  16. Gupta A, Cooper ZA, Tulapurkar ME, Potla R, Maity T, Hasday JD, et al. Toll-like receptor agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and extracellular release. J Biol Chem 2013; 288(4): 2756-66.
  17. Han Y, Li Y, Chen J, Tan Y, Guan F, Wang X. Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharides. Mar Drugs 2013; 11(2): 363-76.
  18. García-González PA, Maggi J, Schinnerling K, Sepúlveda-Gutiérrez A, Soto L, Neira O, et al. Regulation of tolerogenic features on dexamethasone-modulated MPLA-activated dendritic cells by MYC. Front Immunol 2019; 10: 1171.
  19. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature 2009; 458(7242): 1191-5.
  20. Nguyen QT, Kim E, Yang J, Lee C, Ha DH, Lee CG, et al. E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine. Vaccines (Basel) 2020; 8(2): 306.
  21. Haghighat S, Siadat SD, Sorkhabadi SMR, Sepahi AA, Mahdavi M. Cloning, expression and purification of autolysin from methicillin-resistant Staphylococcus aureus: potency and challenge study in Balb/c mice. Mol Immunol 2017; 82: 10-8.
  22. Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 2010; 16(9): 1408-13.
  23. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213-20.
  24. Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine 2018; 36(40): 6007-16.
  25. Geall A, Settembre E. Immunogenic combination compositions and uses thereof. Google Patents; 2018.
  26. Reed SG, Hsu FC, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immuno 2016; 41: 85-90.
  27. Kalali Y, Haghighat S, Mahdavi M. Passive immunotherapy with specific IgG fraction against autolysin: analogous protectivity in the MRSA infection with antibiotic therapy. Immunol Lett 2019; 212: 125-31.
  28. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol 2012; 24(3): 310-5.
  29. Patil HP, Murugappan S, Ter Veer W, Meijerhof T, De Haan A, Frijlink HW, et al. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. J Control Release 2014; 174: 51-62.
  30. Cheng R, Fontana F, Xiao J, Liu Z, Figueiredo P, Shahbazi M-A, et al. Recombination monophosphoryl lipid A-derived vacosome for the development of preventive cancer vaccines. ACS Appl Mater Interfaces 2020; 12(40): 44554-62.
Journal of Isfahan Medical School
Volume 41, Issue 737
1st Week, December
November and December 2023
Pages 835-845

Files

History

  • Receive Date: 13 July 2023
  • Revise Date: 20 November 2023
  • Accept Date: 20 November 2023

Share

How to cite

Statistics